EP Patent

EP3953473A1 — Sirt1-sarna compositions and methods of use

Assigned to Mina Therapeutics Ltd · Expires 2022-02-16 · 4y expired

What this patent protects

The disclosure relates to a saRNAs useful in upregulating the expression of the SIRT1 gene and therapeutic compositions comprising the saRNA. Methods of using the saRNA and the therapeutic compositions are also provided.

USPTO Abstract

The disclosure relates to a saRNAs useful in upregulating the expression of the SIRT1 gene and therapeutic compositions comprising the saRNA. Methods of using the saRNA and the therapeutic compositions are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP3953473A1
Jurisdiction
EP
Classification
—
Expires
2022-02-16
Drug substance claim
No
Drug product claim
No
Assignee
Mina Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.